Collaborators

Collaborators

National Science Foundation

Small Business Innovation Research Grant Phase I & II

Care Progress is the proud recipient of two major National Science Foundation grants, Small Business Innovation Research Grant Phase I and Small Business Innovation Research Grant Phase II. Both awards support the development of CarePrompter’s software platform, product design, and extensive product testing.

Georgetown University’s Lombardi Comprehensive Cancer Care Center

Principle Investigator: John Marshall, MD

John Marshall, MD, is a global leader in the research and development of drugs for colon cancer and other GI cancers. He is the principle investigator of over 150 clinical trials, at the local as well as the national level. Dr. Marshall is the clinical director of oncology for Georgetown University Hospital, associate director for clinical care of the Lombardi Comprehensive Cancer Center, and chief of the Division of Hematology-Oncology. He is widely published in the field of clinical oncology, reviews manuscripts for eight journals, and holds peer-reviewed grants from the National Institutes of Health.

In 2009, Dr. Marshall became the founding director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer. Combining expertise in molecular medicine, translational research, and a patient-centered philosophy, the Ruesch Center is dedicated to realizing the dream of individualized curative therapies through research, care and advocacy.

Hackensack University Medical Center

 

Principle Investigator: Martin E. Gutierrez, MD

Dr. Martin Gutierrez is the director of Drug Discovery and Phase I Unit at John Theurer Cancer Center at Hackensack University Medical Center. Dr. Gutierrez specializes in medical oncology, thoracic and gastrointestinal oncology, and is board certified in internal medicine, medical oncology and hematology.

Dr. Gutierrez is a member of the American College of Physicians, Massachusetts Medical Society, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, National Surgical Adjuvant Breast and Bowel Project, Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and Cancer Trials Support Unit. He is a reviewer for the scientific journals Clinical Cancer Research, The Cancer Journal and Cancer Chemotherapy and Pharmacology.

Rush University Medical Center

Principle Investigator: Nicklas Pfanzelter, MD

Dr. Pfanzelter is an Assistant Professor of Medicine in the Section of Medical Oncology for the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center. He is a medical oncologist who specializes in the diagnosis and treatment of prostate, kidney, bladder, testicular cancers and melanoma. Dr. Pfanzelter recently co-authored an academic article titled Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma and continues to conduct academic research through his professorship.

Dr. Nicklas Pfanzelter received his Bachelor of Science from University of Illinois at Urbana-Champaign, his MD from the University of Chicago Pritzker School of Medicine, and his Masters of Science in Epidemiology from the University of Pennsylvania.

Christus Spohn Health System

Principle Investigator: Sheryln Wachtel, Ph.D

Dr. Wachtel is the Regional Director of Clinical Research & Community Health Development at Christus Spohn Health System. Over her careers, she has garnered experience in Critical Care, Emergency Medicine, and Trauma in the roles of staff nurse, charge nurse, nurse manager, supervisor and service line administrator. Dr. Wachtel has also previously held a faculty position at TAMUCC School of Nursing where she taught both undergraduate and graduate Nursing courses.

She holds an Advanced Practice Nurse (APN) license as a Clinical Nurse Specialist – Critical Care (CNS – CC) with over 15 years managing patient outcomes in the ICU using evidence-based practices and methodologies. Her scientific investigative focus is clinical technology research.